Q Therapeutics Inc., a Salt Lake City-based developer of cell-based therapies for CNS disorders, has raised the first tranche of a $15 million Series B round. vSpring Capital led the deal, and was joined by Invitrogen Corp., Epic Ventures (fka Wasatch Venture Fund), Toucan Capital,
PRESS RELEASE
Q Therapeutics, Inc., a biotechnology company pursuing cell-based therapies for the central nervous system (CNS), announced today that it has closed on a first tranche of its $15 million Series B financing. The round was led by vSpring Capital; other investors include Invitrogen Corporation, Epic Ventures (Formerly Wasatch Venture Fund), Toucan Capital,
Q is conducting preclinical studies to support the filing of an Investigational New Drug Application with the FDA using Q-Cells
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.